These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

289 related items for PubMed ID: 17671193

  • 1. The survival kinase Mirk/Dyrk1B is a downstream effector of oncogenic K-ras in pancreatic cancer.
    Jin K, Park S, Ewton DZ, Friedman E.
    Cancer Res; 2007 Aug 01; 67(15):7247-55. PubMed ID: 17671193
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Activation of Raf-1 in human pancreatic adenocarcinoma.
    Berger DH, Jardines LA, Chang H, Ruggeri B.
    J Surg Res; 1997 Apr 01; 69(1):199-204. PubMed ID: 9202670
    [Abstract] [Full Text] [Related]

  • 9. K-Ras promotes growth transformation and invasion of immortalized human pancreatic cells by Raf and phosphatidylinositol 3-kinase signaling.
    Campbell PM, Groehler AL, Lee KM, Ouellette MM, Khazak V, Der CJ.
    Cancer Res; 2007 Mar 01; 67(5):2098-106. PubMed ID: 17332339
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Dominant negative MEKK1 inhibits survival of pancreatic cancer cells.
    Hirano T, Shino Y, Saito T, Komoda F, Okutomi Y, Takeda A, Ishihara T, Yamaguchi T, Saisho H, Shirasawa H.
    Oncogene; 2002 Aug 29; 21(38):5923-8. PubMed ID: 12185592
    [Abstract] [Full Text] [Related]

  • 13. Molecular target-based therapy of pancreatic cancer.
    Lebedeva IV, Sarkar D, Su ZZ, Gopalkrishnan RV, Athar M, Randolph A, Valerie K, Dent P, Fisher PB.
    Cancer Res; 2006 Feb 15; 66(4):2403-13. PubMed ID: 16489047
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Molecular consequences of silencing mutant K-ras in pancreatic cancer cells: justification for K-ras-directed therapy.
    Fleming JB, Shen GL, Holloway SE, Davis M, Brekken RA.
    Mol Cancer Res; 2005 Jul 15; 3(7):413-23. PubMed ID: 16046552
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.